For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Xilio Therapeutics Inc (NASDAQ: XLO) was $0.75 for the day, down -0.62% from the previous closing price of $0.75. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 0.11 million shares were traded. XLO stock price reached its highest trading level at $0.765 during the session, while it also had its lowest trading level at $0.75.
Ratios:
Our analysis of XLO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.20.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on August 06, 2025, initiated with a Outperform rating and assigned the stock a target price of $2.
On December 21, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $36 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 39380496 and an Enterprise Value of -57120504. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.24. Its current Enterprise Value per Revenue stands at -1.796 whereas that against EBITDA is 1.354.
Stock Price History:
The Beta on a monthly basis for XLO is -0.04, which has changed by -0.30733943 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -4.61%, while the 200-Day Moving Average is calculated to be -2.92%.
Shares Statistics:
XLO traded an average of 754.92K shares per day over the past three months and 549860 shares per day over the past ten days. A total of 51.83M shares are outstanding, with a floating share count of 22.68M. Insiders hold about 56.79% of the company’s shares, while institutions hold 8.08% stake in the company. Shares short for XLO as of 1763078400 were 6913181 with a Short Ratio of 9.16, compared to 1760486400 on 5251586. Therefore, it implies a Short% of Shares Outstanding of 6913181 and a Short% of Float of 19.009999999999998.
Earnings Estimates
A detailed examination of Xilio Therapeutics Inc (XLO) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.49 and -$0.49 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.24, with 2.0 analysts recommending between -$0.18 and -$0.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 1 analysts. It ranges from a high estimate of $10.9M to a low estimate of $10.9M. As of. The current estimate, Xilio Therapeutics Inc’s year-ago sales were $1.72MFor the next quarter, 1 analysts are estimating revenue of $6.9M. There is a high estimate of $6.9M for the next quarter, whereas the lowest estimate is $6.9M.
A total of 1 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $41M, while the lowest revenue estimate was $41M, resulting in an average revenue estimate of $41M. In the same quarter a year ago, actual revenue was $6.34MBased on 2 analysts’ estimates, the company’s revenue will be $59.77M in the next fiscal year. The high estimate is $81.75M and the low estimate is $37.8M.
